$0.1542
-0.0116-7%
Last update: Nov 11, 8:40 AM
Theriva Biologics Inc
TOVXAMEX
The average analyst price target for Theriva Biologics is $1, 554.9% above the current price. The one analyst covering it rates it Buy. The latest change came on Mar 31, 2026, when Maxim Group upgraded Theriva Biologics from Hold to Buy with a $1 price target.
Price Target Range — 2 Quarters
Analyst Consensus — 1 Analysts
Rating Trend — Last 9 Months
